| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 3,408 | 3,542 | 15.08. | |
| 3,438 | 3,508 | 14.08. |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.05. | Surgical Science Sweden AB: Report from the Annual General Meeting of Surgical Science Sweden AB (publ) | 308 | GlobeNewswire (Europe) | At Surgical Science Sweden AB (publ)'s Annual General Meeting today, the following, amongst other things, was decided:
To adopt the company's and the group's income statements and balance sheets for... ► Artikel lesen | |
| 20.05. | Surgical Science Sweden AB Bottom Line Retreats In Q1 | 9 | RTTNews | ||
| 20.05. | Surgical Science Sweden AB: Interim report January - March 2026: A solid start to the year | 393 | GlobeNewswire (Europe) | First quarter 2025 (Jan-Mar)
Net sales amounted to SEK 235.5 (250.7) million, a decrease of 6 percent compared with the corresponding period in the preceding year. Calculated in local currencies, sales... ► Artikel lesen | |
| 25.04. | Globaler Mega-Deal: Bioxyne und Aurora Cannabis könnten den Markt umkrempeln! | Small- & Micro Cap Investment | |||
| SURGICAL SCIENCE SWEDEN Aktie jetzt für 0€ handeln | |||||
| 19.02. | Surgical Science Sweden AB: Year-end report 2025: Profitability in line with financial targets | 598 | GlobeNewswire (Europe) | Fourth quarter 2025 (October - December)Net sales amounted to SEK 268.9 (251.5) million, an increase of 7 percent compared with the corresponding period in the preceding year. Calculated in local currencies... ► Artikel lesen | |
| 08.12.25 | Surgical Science Sweden AB: Surgical Science announces new financial targets and initiates the process of a listing transfer | 622 | GlobeNewswire (Europe) | Surgical Science today communicates new financial targets. Growth shall amount to 10-15% annually with an adjusted EBIT of at least 15%. The company estimates that the targets will be met in 2027. As... ► Artikel lesen | |
| 25.11.25 | Surgical Science Sweden AB: Intuitive cancels the MoU and reverts to existing agreements. Surgical Science estimates that this will have a negative impact on license revenues of around SEK 60-90 million in 2026, compared to 2025 | 1.423 | GlobeNewswire (Europe) | The Memorandum of Understanding (MoU) signed between the companies on January 15 this year did not turn into a signed legal agreement. As a consequence of this, Surgical Science will not reach the previously... ► Artikel lesen | |
| 13.11.25 | Surgical Science Sweden AB: Interim report January-September 2025: Progress in the right direction | 530 | GlobeNewswire (Europe) | Third quarter 2025 (July - September)Net sales amounted to SEK 263.6 (231.8) million, an increase of 14 percent compared with the corresponding period in the preceding year. Calculated in local currencies... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 47,080 | -1,22 % | EQS-News: Fresenius SE & Co. KGaA: Fitch Ratings hebt Ausblick für Fresenius SE von stabil auf positiv an | EQS-News: Fresenius SE & Co. KGaA
/ Schlagwort(e): Rating
Fitch Ratings hebt Ausblick für Fresenius SE von stabil auf positiv an
10.08.2026 / 14:30 CET/CEST
Für den... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 41,040 | +0,12 % | EQS-CMS: Fresenius Medical Care AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Fresenius Medical Care AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b) der Verordnung (EU) Nr. 596/2014
Fresenius Medical Care AG: Veröffentlichung... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 39,310 | +0,69 % | EQS-CMS: Siemens Healthineers AG: Veröffentlichung einer Kapitalmarktinformation | EQS Zulassungsfolgepflichtmitteilung: Siemens Healthineers AG
/ Bekanntmachung nach Art. 5 Abs. 1 lit. b), Abs. 3 der Verordnung (EU) Nr. 596/2014, zuletzt geändert durch die Verordnung... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 32,280 | +6,04 % | Carl Zeiss Meditec Aktie: UBS zieht die Reißleine | UBS wird für die Carl Zeiss Meditec Aktie deutlich pessimistischer und stuft den Titel von "Neutral" auf "Sell" ab. Gleichzeitig sinkt das Kursziel von 25,00 auf 22,60 Euro. Auch Barclays und Goldman... ► Artikel lesen | |
| ECKERT & ZIEGLER | 13,590 | -0,44 % | Eckert & Ziegler: Q2 review: underlying business solid, valuation attractive: Despite a slight consensus miss with Q2, ... | Eckert & Ziegler reported H1 results: adj. EBIT grew 10% yoy ex license, with the margin up 1.2pp to 22.3%, while reported adj. EBIT fell 6% yoy to € 33.3m against a base carrying € 5m of license income... ► Artikel lesen | |
| INTUITIVE SURGICAL | 341,00 | +0,04 % | Intuitive Surgical: Dieses FDA-Signal verändert die Lage | ||
| UNITEDHEALTH | 347,00 | -0,12 % | Luigi Mangione pleads guilty in federal case over murder of UnitedHealthcare CEO Brian Thompson | ||
| DRAEGERWERK | 110,00 | -0,72 % | dpa-AFX-Überblick: UNTERNEHMEN - Die wichtigsten Meldungen vom Wochenende | Stabilus: Finanzvorstand geht - Konzernchef übernimmt übergangsweise KOBLENZ - Der Auto- und Industriezulieferer Stabilus muss sich einen neuen Finanzvorstand suchen. Andreas Jaeger habe den Aufsichtsrat... ► Artikel lesen | |
| MEDTRONIC | 78,90 | 0,00 % | Medtronic structural heart leader appointed CEO of Versa Vascular | ||
| GERRESHEIMER | 27,160 | +0,97 % | EQS-PVR: Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Gerresheimer AG
Gerresheimer AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of... ► Artikel lesen | |
| THERMO FISHER | 512,00 | +0,71 % | Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist | The transaction establishes an independent company, with the Microbiology business providing the foundation of a global microbiology diagnostics platform serving the clinical, food safety and... ► Artikel lesen | |
| TELADOC HEALTH | 5,862 | -0,51 % | Teladoc Health, Inc.: Teladoc Health Appoints Financial Executive Mark Anquillare to Its Board of Directors | NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health (NYSE: TDOC), the global leader in virtual care, today announced the appointment of Mark V. Anquillare to its board of directors. Mr. Anquillare... ► Artikel lesen | |
| STRATEC | 22,000 | +9,18 % | Stratec SE: Die Erholung im zweiten Quartal ist ermutigend; Geschäftsjahr 2026 hängt von Umsetzung im Q4 ab; HALTEN. | Stratec's Q2 zeigte eine klare Erholung, mit einem Umsatzanstieg von 2,4% in konstanten Währungen und einem mehr als verdoppelten bereinigten EBIT, was die Marge auf 11,9% anhebt. Analyzer Systems blieb... ► Artikel lesen | |
| HEARTFLOW | 42,110 | +0,07 % | Heartflow, Inc.: Heartflow Reports Second Quarter 2026 Financial Results and Raises Full Year 2026 Guidance | SAN FRANCISCO, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for diagnosing coronary artery disease (CAD), today reported financial results... ► Artikel lesen | |
| AVEANNA HEALTHCARE | 12,310 | -0,08 % | Biotech Stocks At 52-Week Highs - PARK +10%, AVAH +24%, CADL +10% On Q2 Reports, LH, COAG | LONDON (dpa-AFX) - The following biotech stocks reached 52-week highs on August 13, 2026, driven by key catalysts such as positive quarterly reports and the issuance of increased guidance figures.Park... ► Artikel lesen |